// App-Quantinova.ai

7012 : Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.

Researchers

Presenter

  • Vikas Gupta

Principal Investigators

  • Ruben A. Mesa

  • Jason R. Gotlib

  • John F. DiPersio

  • John V. Catalano

  • Michael W.N. Deininger

  • Carole Brennan Miller

  • Richard T. Silver

  • Moshe Talpaz

  • Elliott F. Winton

  • Jimmie Huling Harvey

  • Murat O. Arcasoy

  • Elizabeth O. Hexner

  • Roger M. Lyons

  • Ronald Paquette

  • Azra Raza

  • Deanna Kornacki

  • Kang Sun

  • Hagop M. Kantarjian

Medical Centers

  • Biostatistics, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Mayo Clinic, Scottsdale, AZ

  • Stanford University School of Medicine/Stanford Cancer Center, Stanford, CA

  • Washington University School of Medicine, St. Louis, MO

  • Frankston Hospital and Department of Clinical Haematology, Frankston, Australia

  • Oregon Health and Science University, Portland, OR

  • St. Agnes Cancer Institute, Baltimore, MD

  • Weill Cornell Medicine, New York, NY

  • University of Michigan, Ann Arbor, MI

  • Emory University School of Medicine, Atlanta, GA

  • Birmingham Hematology Oncology Associates, Birmingham, AL

  • Duke University Health System, Durham, NC

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • Cancer Care Centers of South Texas/US Oncology, San Antonio, TX

  • Ronald Reagan UCLA Medical Center, University of California, Los Angeles, CA

  • Columbia University Medical Center, New York, NY

  • Incyte Corporation, Wilmington, DE

Locations

  • United States

  • Canada

  • Australia

Companies

  • Incyte Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelofibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Cross Over

Phase

  • III

Study Id's

  • NCT00952289

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved